Physician_Profile_ID,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID,Total_Amount_of_Payment_USDollars,Date_of_Payment,Form_of_Payment_or_Transfer_of_Value,Record_ID,Name_of_Associated_Covered_Drug_or_Biological1,Name_of_Associated_Covered_Drug_or_Biological2,Name_of_Study,Research_Information_Link,Context_of_Research
35650,"Takeda Development Center Americas, Inc.",IL,100000000338,1414.00,08/26/2013,"Cash or cash equivalent",106110930,Actos,"","Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD","",""
35650,"Takeda Development Center Americas, Inc.",IL,100000000338,825.99,08/26/2013,"Cash or cash equivalent",106110927,Actos,"","Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD","",""
35650,"GlaxoSmithKline, LLC.",NC,100000005449,92.20,05/28/2014,"Cash or cash equivalent",208680858,"","","A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events  MACE","",""
35650,"GlaxoSmithKline, LLC.",NC,100000005449,1.08,05/28/2014,"Cash or cash equivalent",208680862,"","","A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events  MACE","",""
